A drug to treat advanced prostate cancer should be given to patients on the NHS, a health watchdog has said.
Abirateron, marketed as Zytiga, can extend the lives of late-stage cancer sufferers by more than three months.
The National Institute for Health and Clinical Excellence (Nice) revised its recommendations after fresh information from manufacturer Janssen, and the new draft guidance was welcomed by experts.
More top news
Andre Luzganov, who shot dramatic video of the attack the weekend, told ITV News his family has left and will not be returning to Mariupol.
A call operator at NHS 111, which was designed to relieve pressure on emergency services, tells ITV News the system is struggling to cope.
Shell chief executive Ben Van Beurden says the full effect of oil price slump is yet to be felt. In the meantime tough decisions lie ahead.